Actions
Pages
Subscribe for newsletter
Stories
Oil giant ExxonMobil is venturing into lithium production and aims to be a major player in the EV battery industry by establishing its first drilling operation in southern Arkansas.
The demand for lithium is set to quadruple by 2030 due to its role in rechargeable batteries for electric vehicles, phones, laptops, and other electronic devices. ExxonMobil’s move aligns with the increasing global call for sustainable energy sources while strengthening domestic lithium supplies.
“This landmark project applies decades of ExxonMobil expertise to unlock vast supplies of North American lithium with far fewer environmental impacts than traditional mining operations,” said Dan Ammann, president of ExxonMobil Low Carbon Solutions.
Future expansion of lithium production is on the horizon, with ExxonMobil exploring global opportunities and potential collaborations with EV manufacturers.
ExxonMobil’s history in innovative automotive solutions, including the development of the first lithium-ion battery, underpins this venture, demonstrating its longstanding commitment to technological advancements in energy.
The project not only diversifies ExxonMobil's portfolio but also potentially reshapes the global lithium market, challenging the current dominance of Australia, China, and South America in lithium production.
Story
Ivy Farm Technologies, is a UK-based, Oxford University-funded company, has figured out how to cultivate minced meat in just two weeks, a groundbreaking advancement with significant environmental implications.
The demand for meat is expected to grow by 73% in the next 30 years. This isn’t sustainable and would lead to mass deforestation and a huge increase in greenhouse gas emissions from animal agriculture. The cultivated meat industry addresses the impending global food shortage, climate change and has the potential to boost the economy.
Regulatory hurdles in the UK are hindering the growth of the cultivated meat industry, potentially placing it at a disadvantage compared to countries with more favorable regulatory environments like the US and Singapore.
“Cultivated meat is real meat, only it’s made differently. The process involves one of the most natural processes on the planet - cell replication. In fact, the process is similar to the way in which popular cultured or fermented drinks and foods, such as beer or kefir, are made.” - Ivy Farm CEO Richard Dillon
Peer-reviewed studies indicate that cultivated meat has the potential to reduce greenhouse gas emissions by as much as 92% and decrease air pollution by up to 94%. Furthermore, this innovative meat production method could require 66% less water and use 90% less land compared to traditional beef production.
Ivy Farm aims to gain regulatory approval in major global markets, with plans to serve consumers in premium restaurants and supermarkets. Their economic contributions and sustainability focus could reshape the future of meat production.
There still seems to be a reluctance to embrace lab grown meat. Call it “non-Lindy”. We are keeping our eyes on this sector to see how it develops.
Story
Steve Cohen, the American billionaire and New York Mets owner, is steering the biopharma industry into a new era with his multi-million dollar infusion into psychedelic research. This surge of activity, which parallels the initiatives by Peter Thiel and Blake Mycoskie, gains further validation from the FDA's breakthrough therapy designations.
These strategic investments reflect a larger trend of institutional validation for psychedelics as viable therapeutic agents. The involvement of billionaires like Cohen, Thiel, and Mycoskie indicates a growing confidence in psychedelic medicine's potential to effectively treat conditions such as PTSD and depression, potentially reshaping the future of mental healthcare.
Expectations are high for more breakthrough therapy designations from the FDA, as well as a surge in both private and public funding for psychedelic research, setting a fast-tracked pace for the industry's growth.
Steve Cohen's push into psychedelic research isn't just an investment—it's a declaration that this field is poised for major league status within biopharma. As these therapies edge closer to regulatory approval and public acceptance, we may be witnessing the dawn of a new era in mental health treatment, backed by the conviction and capital of some of the world's most influential billionaires.
Story
Innovators
Scroll
Open
Close